Responses
Poster Presentations
Spondyloarthritis - treatment
THU0204 Correlation Between Serum Level of Infliximab or Adalimumab and Clinical Response in Spondyloarthritis Seems too Strong to Give the Opportunity of an Interest on Dosage for Therapeutic Adaptation
Compose a Response to This Article
Other responses
No responses have been published for this article.